| |
rhTM group (n = 52)
|
Non-rhTM group (n = 45)
|
P value
|
|---|
|
Age (years)
|
66 (54–74)
|
65 (51–73)
|
0.90
|
|
Male, n (%)
|
35 (67.3)
|
35 (77.8)
|
0.27
|
|
Body mass index
|
22.1 (19.4–24.0)
|
23.1 (20.6–25.9)
|
0.23
|
|
APACHE II
|
25 (22–27)
|
25 (21–30)
|
0.33
|
|
SOFA score at ICU admission
|
9 (6–10)
|
9 (7–11)
|
0.34
|
|
Focus of infection
|
|
Abdomen
|
22
|
15
| |
|
Lung
|
19
|
16
| |
|
Urogenital tract
|
3
|
3
| |
|
Skin and soft tissue
|
3
|
2
| |
|
CRBSI
|
2
|
1
| |
|
Miscellaneous
|
3
|
8
| |
|
Septic shock, n (%)
|
37 (71.2)
|
33 (73.3)
|
0.83
|
|
DIC score
|
|
JAAM DIC
|
6 (5–7)
|
6 (5–7)
|
0.52
|
|
ISTH overt DIC
|
6 (5–6)
|
6 (4–6)
|
0.76
|
|
Anticoagulants, n (%)
|
|
rhTM
|
52 (100)
|
-
| |
|
Heparin
|
-
|
18 (40)
| |
|
Antithrombin
|
30 (57.7)
|
18 (40)
|
0.10
|
|
Others
|
-
|
8 (17.8)
| |
|
Steroids, n (%)
|
32 (61.5)
|
18 (40)
|
0.16
|
|
KDIGO classification
| | |
0.57
|
|
Stage 1
|
16
|
17
| |
|
Stage 2
|
19
|
12
| |
|
Stage 3
|
17
|
16
| |
|
Timing of RRT from ICU admission (h)
|
3.8 (2.0–7.9)
|
4.0 (3.0–5.8)
|
0.67
|
- Data are presented as medians (IQR). The body mass index is the weight in kilograms divided by the square of the height in meters. The SOFA score ranges from 0 to 24, with higher scores indicating more severe organ failure. The APACHE II score ranges from 0 to 71, with higher scores indicating more severe disease and a higher risk of death. Acute kidney injury was defined according to the KDIGO classification. Stage 3 of the KDIGO classification is defined as a serum creatinine level three times the baseline level or an increase of ≥ 4.0 mg per deciliter, oliguria (urine output < 0.3 mL per kilogram of body weight per hour for ≥ 24 h), or anuria for ≥ 2 h. The baseline serum creatinine levels were determined using values measured at 12 months preceding the ICU stay or were estimated
- ICU intensive care unit, IQR interquartile range, CRBSI catheter-related bloodstream infections, DIC disseminated intravascular coagulation, JAAM Japanese Association for Acute Medicine, ISTH International Society on Thrombosis and Haemostasis, RRT renal replacement therapy, rhTM recombinant human soluble thrombomodulin, SOFA Sequential Organ Failure Assessment, APACHE II Acute Physiology and Chronic High Evaluation II, KDIGO Kidney Disease Improving Global Outcomes
